Related references
Note: Only part of the references are listed.Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment
Sofie Singbrant et al.
BLOOD (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
A Blueprint for Advancing Genetics-Based Cancer Therapy
William R. Sellers
CELL (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Preclinical development of molecular-targeted agents for cancer
Alberto Ocana et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Jinsong Hu et al.
BLOOD (2010)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen et al.
BLOOD (2010)
Raising the bar for cancer therapy models
Giulio Francia et al.
NATURE BIOTECHNOLOGY (2010)
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh et al.
NATURE BIOTECHNOLOGY (2010)
Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study
J-F Rossi et al.
BRITISH JOURNAL OF CANCER (2009)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
CS Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Antimyeloma efficacy of thalidomide in the SCID-hu model
S Yaccoby et al.
BLOOD (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
YP Shou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
